Nucleotide dimers suppress HIV expression in vitro.

Area of Science:

• Virology
• Medicinal Chemistry
• Molecular Biology

Background:

• Human Immunodeficiency Virus (HIV) remains a significant global health challenge.
• Developing effective antiviral agents with improved therapeutic indices is crucial for HIV treatment.
• Nucleotide analogs are a cornerstone of current antiretroviral therapy.

Purpose of the Study:

• To synthesize and evaluate novel nucleotide homo- and heterodimers for anti-HIV properties.
• To compare the efficacy and cytotoxicity of these dimers against their constituent monomers.
• To assess the potential of nucleotide dimers as next-generation anti-HIV agents.

Main Methods:

• Synthesis of nucleotide dimers: AZT-P-ddA, AZT-P(CyE)-ddA, AZT-P-ddI, and AZT-P-AZT.
• In vitro anti-HIV assays using MT-2 cells infected with HIV.
• Evaluation of inhibition of syncytia formation, reverse transcriptase production, and p24 antigen expression.
• Cytotoxicity assessment of dimers and monomers.

Main Results:

• All synthesized dimers and their respective monomers inhibited HIV replication markers.
• Nucleotide heterodimers exhibited greater anti-HIV potency on an equimolar basis compared to monomers.
• Enhanced cytotherapeutic indices were observed for heterodimers over monomers.
• AZT-P-ddA demonstrated significant anti-HIV activity and favorable therapeutic index.

Conclusions:

• Nucleotide dimers, particularly heterodimers like AZT-P-ddA, represent a promising class of compounds for HIV therapy.
• These dimers offer enhanced anti-HIV potency and improved safety profiles over their monomeric counterparts.
• Further preclinical and clinical evaluation of these nucleotide dimers is strongly recommended.